<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="762">
  <stage>Registered</stage>
  <submitdate>5/09/2005</submitdate>
  <approvaldate>5/09/2005</approvaldate>
  <nctid>NCT00167518</nctid>
  <trial_identification>
    <studytitle>Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)</studytitle>
    <scientifictitle>Phase II/III Intravitreal Triamcinolone for Treatment of Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ORIA Esme Anderson Grant</secondaryid>
    <secondaryid>JDRF 1-2003-767</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetic Macular Oedema</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Triamcinolone acetate

Treatment: drugs: Triamcinolone acetate


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome> Proportion of treated versus untreated eyes with improvement of visual acuity by 5 letters or more on the ETDRS chart at 24 months, no less than 3 months after the most recent treatment episode. An interim analysis of the primary and secondary outcome</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome> Incidence of moderate or severe adverse effects related to treatment</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome> Any change of visual acuity (treated versus untreated eyes) at 3 months and 24 months after treatment</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Proportion of treated versus untreated eyes with reduction of macular thickness as demonstrated with OCT at 3 months and 24 months. Both absolute change and percentage change will be analysed.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Changes in semi-quantitative grading of cataract at 3 months and 24 months.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Clinically significant diabetic macular oedema involving the fovea in one or both eyes
             (phakic and/or pseudophakic) which persists at least 3 months after adequate macular
             photocoagulation.

          -  best corrected visual acuity in the affected eye(s) 6/9 or worse</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Glaucoma which is uncontrolled or is controlled but with glaucomatous visual field
             defects

          -  Loss of vision due to other causes (e.g. age related macular degeneration, myopic
             macular degeneration)

          -  Significant macular ischemia (FFA)

          -  No useful vision in fellow eye

          -  Known allergies to triamcinolone acetate or steroids

          -  Patient is already under systemic treatment with &gt; 5mg prednisolone (or equivalent)
             daily.

          -  Intercurrent severe disease such as septicaemia

          -  Any condition which would affect follow-up or photographic documentation (e.g.
             geographical, psycho-social, media opacities)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Save Sight Institute, Sydney/Sydney Eye Hospital Campus, University of Sydney - Sydney</hospital>
    <postcode>2000 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The trial will test the hypothesis that an intravitreal injection of triamcinolone is safe
      and efficacious for patients with clinically significant diabetic macular oedema that is
      recalcitrant to conventional laser therapy</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00167518</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mark C Gillies, MBBS, PhD</name>
      <address>Save Sight Institute, Deaprtment of Clinical Ophthalmology, University of Sydney</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>